On July 22, we mentioned Cassava Sciences was one of the hottest stocks on the market.
In fact, since mentioning it, the stock ran from about $108 to $144.63.
All thanks to a build-up of excitement ahead of its presentation at the 2021 Alzheimer’s Association International Conference. Today, though, the stock is down about $11 a share, which could create another strong buy opportunity here, especially after it announced a positive biomarker for an open-label study of simufilam for Alzheimer’s.
In a clinical study funded by the National Institutes of Health (NIH), simufilam significantly improved all measured biomarkers in patients with Alzheimer’s disease following 6 months of open-label treatment, according to a company release.
“Six months of simufilam treatment robustly improved brain biomarkers,” said Remi Barbier, President and CEO. “In this same study simufilam also improved cognition. These data suggest simufilam has potential to provide durable treatment effects for people living with Alzheimer’s.”
With SAVA, once the pullback has exhausted itself, it’s a strong buy.
